---

            

• 

  Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets—PART 2: Approaches Beyond First-Line Therapy, and Novel Biologic Agents Under Investigation

  July 15, 2017
  A frequent quandary for oncologists is the selection of chemotherapy and biologic therapy for patients with metastatic colorectal cancer in second-line and higher treatment settings.
• 

  The Biology of Extending Survival in Metastatic Colorectal Cancer

  July 13, 2017
  Research is helping define subsets in colorectal cancer that, increasingly, impact everyday clinical practice. The resulting enhanced understanding of the underlying biology of the disease has led to a more nuanced treatment approach.
• 

  Subtle molecular changes along the upper digestive tract could guide cancer therapy

  June 30, 2017
  Based on a new molecular study of tissues biopsied from various parts of the upper digestive tract, researchers at Georgetown Lombardi Comprehensive Cancer Center have identified significant, if subtle, differences in gene mutations and other...
• 

  Good IDEA: Drop Adjuvant Chemo From 6 to 3 Months in CRC

  June 12, 2017
  Dr John Marshall reports on the practice-changing results of the IDEA study in stage III colorectal cancer looking at duration of adjuvant chemotherapy, as presented at the ASCO plenary session.
• 

  John Marshall, MD, and John Neil Primrose, PhD, MBBS, on Biliary Tract Cancer: Results From the BILCAP Trial

  June 11, 2017
  John Marshall, MD, of Georgetown University, and John Neil Primrose, PhD, MBBS, of the University of Southampton, discuss the potentially practice-changing findings on adjuvant capecitabine for biliary tract cancer. (Abstract 4006)
• 

  John Marshall, MD, and Qian Shi, PhD, on Colon Cancer: Results of the IDEA Trial

  June 11, 2017
  John Marshall, MD, of Georgetown University, and Qian Shi, PhD, of the Mayo Clinic, discuss study findings on shortening the duration of adjuvant oxaliplatin-based therapy, linked to neurotoxicity, for patients with stage III colon cancer. (Abstract LBA1)
• 

  ASCO 2017: Impact of Patient Age on Molecular Alterations in Colorectal Tumors

  June 7, 2017
  Younger patients with colon cancer appear to have more than three times as many mutations in their tumors as older patients, which could lead to more effective treatment decisions, according to researchers at Georgetown Lombardi Comprehensive Cancer Center.
• 

  Will Adjuvant Oxaliplatin Data Change Practice in Colon Cancer?

  May 26, 2017
  Dr John Marshall previews the GI cancer studies being presented at ASCO with his picks for the ones to watch, and predicts that a plenary presentation may be practice-changing.
• 

  New finding could lead to more effective treatment decisions for younger colorectal cancer patients

  May 18, 2017
  Younger colon cancer patients appear to have more than three times as many mutations in their tumors as older patients, which could lead to more effective treatment decisions, say researchers at Georgetown Lombardi Comprehensive Cancer Center.
• 

  A Counterintuitive Finding That Could Benefit Younger Colorectal Cancer Patients

  May 17, 2017
  Younger colon cancer patients appear to have more than three times as many mutations in their tumors as older patients, which could lead to more effective treatment decisions, say researchers at Georgetown Lombardi Comprehensive Cancer Center.
• 

  Deficiencies in Repair of DNA Identified in Many Types of Solid Tumors

  May 17, 2017
  A new investigation of more than 48,000 stored tumor samples finds evidence of a key deficiency in a repair mechanism designed to keep DNA from being mutated and causing cancer.
• 

  Caris Life Sciences Appoints John Marshall, M.D., as Chief Medical Officer

  May 17, 2017
  Caris Life Sciences appoints John Marshall, M.D., as Chief Medical Officer, and will direct research efforts and guide strategies for tumor profiling.
• 

  Genomic Findings Reshaping CRC Field

  May 16, 2017
  Extensive studies into molecular aberrations in colorectal cancer are yielding fresh insights into the potential clinical utility of checkpoint immunotherapies, genetic testing, and tumor-sidedness implications.

Sign up to recieve announcements, updates, and newsletters!